EPO and cancer: However, from an epidemiological standpoint, it has been reported that EPO/ESAs administration is associated with an elevation of cardiovascular and venous thromboembolism risks in patients (21) and the induction of tumor progression - independently of the type of cancer or the cancer treatment (22, 23).